Regaining compliance with Nasdaq's minimum bid price requirement is a positive development for VTv Therapeutics. It removes the immediate risk of delisting, which can be a significant concern for investors and can negatively impact stock price. This news is likely to be viewed positively by the market in the short term, as it suggests a level of stability and may attract investors who were previously cautious due to the non-compliance issue.